BS_KXMYBQ6N
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- overall_survival_months
- 60.480000000000004
- os_event
- false
- age_years
- 14.679
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -5.749236938
- umap2_2d
- -0.274227928
- umap1_3d
- -0.059969881
- umap2_3d
- 2.277432119
- umap3_3d
- 1.779883067
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.600
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- INFLAMMATORY_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.490
- ANGIOGENESIS+0.450
- COAGULATION+0.450
- IL2_STAT5_SIGNALING+0.440
- INTERFERON_ALPHA_RESPONSE+0.440
Top 10 suppressed
- SPERMATOGENESIS-0.240
- BILE_ACID_METABOLISM-0.210
- PROTEIN_SECRETION-0.170
- MYC_TARGETS_V1-0.140
- E2F_TARGETS-0.130
- G2M_CHECKPOINT-0.130
- MITOTIC_SPINDLE-0.120
- PEROXISOME-0.080
- ADIPOGENESIS-0.040
- MTORC1_SIGNALING-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KXMYBQ6N | Spinal Cord Ependymoma | — | 0.967 |
| 2 | SRR11296840 | — | — | 0.942 |
| 3 | BS_06AMMCXR | low-grade glioma | — | 0.937 |
| 4 | BS_0QYS36NR | EPN | EPN Tumor | 0.935 |
| 5 | BS_4T0HPZDC | Posterior Fossa Ependymoma | — | 0.934 |
| 6 | BS_4T0HPZDC | EPN | Posterior Fossa EPN | 0.934 |
| 7 | BS_0QYS36NR | Ependymoma NOS | — | 0.931 |
| 8 | BS_VMQMGSJY | high-grade glioma | — | 0.918 |
| 9 | BS_ZVZDDW2G | pleomorphic xanthoastrocytoma(PXA) | — | 0.909 |
| 10 | MDT-AP-1245 | Med | Medulloblastoma | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |